Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

Alzheimer's disease is an incurable neurodegenerative disease primarily affecting the
elderly population. Efficient automated techniques are needed for early diagnosis of …

Alzheimer's disease (AD) is the most common type of dementia. Its diagnosis and
progression detection have been intensively studied. Nevertheless, research studies often …

We built and validated a deep learning algorithm predicting the individual diagnosis of
Alzheimer's disease (AD) and mild cognitive impairment who will convert to AD (c-MCI) …

Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to
validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite …

Early prediction of Alzheimer's disease (AD) is crucial for delaying its progression. As a
chronic disease, ignoring the temporal dimension of AD data affects the performance of a …

Alzheimer's Disease (AD) is a progressive neurodegenerative disease where biomarkers for
disease based on pathophysiology may be able to provide objective measures for disease …

Background Neurofilament light chain protein (NfL) is a promising biomarker of
neurodegeneration. Objectives To determine whether plasma and CSF NfL (1) associate …

Abstract Introduction Bile acids (BAs) are the end products of cholesterol metabolism
produced by human and gut microbiome co-metabolism. Recent evidence suggests gut …

Introduction We investigated plasma proteomic markers of astrocytopathy, brain
degeneration, plasticity, and inflammation in sporadic early-onset versus late-onset …